Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M209133200 on September 30, 2002

J. Biol. Chem., Vol. 277, Issue 49, 47428-47435, December 6, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/49/47428    most recent
M209133200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terao, Y.
Right arrow Articles by Hamada, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terao, Y.
Right arrow Articles by Hamada, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Characterization of a Novel Fibronectin-binding Protein of Streptococcus pyogenes Strains Isolated from Toxic Shock-like Syndrome Patients*

Yutaka TeraoDagger §, Shigetada KawabataDagger §, Masanobu NakataDagger , Ichiro NakagawaDagger , and Shigeyuki HamadaDagger

From the Dagger  Department of Oral and Molecular Microbiology, Osaka University Graduate School of Dentistry, Suita-Osaka 565-0871 and § PRESTO, Japan Science and Technology Corporation, Kawaguchi, Saitama 332-0012, Japan

Received for publication, September 6, 2002, and in revised form, September 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Group A Streptococcus pyogenes has surface-located fibronectin (Fn)-binding proteins known to be a major virulence factor, which adheres to and invades host cells. We present a novel Fn-binding protein of group A streptococcus serotype M3 and M18 strains isolated from patients with toxic shock-like syndrome (TSLS). By searching the whole genome sequence of an M3 strain from a TSLS patient, an open reading frame was found among the putative surface proteins. It possessed an LPXTG motif and Fn-binding repeat domains in the C-terminal region and was designated as FbaB (Fn-binding protein of group A streptococci type B). The fbaB gene was found in all M3 and M18 strains examined, although not in other M serotypes. Furthermore, FbaB protein was expressed on the cell surface of TSLS strains but not on non-TSLS ones. Enzyme-linked immunosorbent assay and ligand blotting revealed that recombinant FbaB exhibits a strong Fn-binding ability. An FbaB-deficient mutant strain showed 6-fold lower adhesion and invasion efficiencies to HEp-2 cells than the wild type. Moreover, mortality was decreased in mice infected with the mutant strain in comparison to the wild type. These data suggest that FbaB is etiologically involved in the development of invasive streptococcal diseases.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Group A streptococcus (GAS)1 is known as the pathogen of streptococcal pharyngitis, although it also causes severe invasive infections, including toxic shock-like syndrome (TSLS) and necrotizing fasciitis. All of these diseases are initiated by the adhesion of GAS to epithelial cells. GAS expresses a wide variety of structural and enzyme proteins that are associated with the bacterial cell wall. It has been demonstrated that several surface proteins have binding abilities to human host proteins, such as fibronectin (Fn) (1), laminin (2), plasmin (3), collagen (4), immunoglobulins (5), and C4b (6). Fn-binding proteins of GAS have also been reported to be adhesins and invasins, including protein F1/SfbI (1, 7), protein F2 (8), SfbII/SOF (9, 10), PFBP (11), and Fba (renamed FbaA) (12). It is interesting to note that each Fn-binding protein is distributed in a particular group of M serotype (7, 12, 13), and highly virulent GAS strains possess one or more Fn-binding proteins. M1 and M49 organisms express FbaA, whereas M6 and M12 organisms retain protein F1/SfbI, and M4 and M28 strains produce both proteins. On the other hand, M3 and M18 organisms do not possess FbaA as well as protein F1/SfbI and SfbII/SOF (7, 12, 13). M3 is a major serotype that has been isolated throughout the world from patients with TSLS and other severe invasive diseases (14-16), and genetic and epidemiological studies have shown that M18 strains are implicated in acute rheumatic fever (17). These findings led us to a hypothesis that there is another Fn-binding protein in M3 or M18 GAS organisms that is involved with their stronger pathogenic capability.

The availability of complete genome sequences of several serotype strains (17-19)2 has shifted focus to the identification and characterization of all gene products that are expressed in GAS, and as a result, several motifs that may be suitable for identification of functional proteins have been found. First, an LPXTG motif known to be the cell-anchoring sequence in Gram-positive cocci (21) has emerged as a target for the identification of new potential surface proteins using the genome sequencing data bases, with the result that GRAB (22), Sc1A (23), Sc1B (24), and FbaA (12) have been reported. Furthermore, various functional motifs among the eukaryotic and prokaryotic species have been added to the protein data bases. Here we report investigation of a novel Fn-binding protein specific for serotype M3 and M18 strains isolated from patients with TSLS in the complete genome data base of the M3 strain using biochemical and bioinformatics approaches.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial Strains, Eukaryotic Cells, and Growth Conditions-- GAS strains were isolated from patients with pharyngitis and TSLS (25) and were grown in Todd-Hewitt broth (Difco) supplemented with 0.2% yeast extract (THY). For antibiotic selection, erythromycin (10 µg/ml) or kanamycin (300 µg/ml) was added to THY medium. Escherichia coli strains XL-10 Gold (Stratagene, La Jolla, CA) and BL21 (Novagen, Madison, WI) were grown in Luria-Bertani (LB) broth (Sigma) or on LB agar plates. Antibiotics were used at the following concentrations: ampicillin (100 µg/ml), erythromycin (250 µg/ml), and kanamycin (30 µg/ml). Relevant characteristics of bacterial strains used in this study are listed in Table I. A human laryngeal epithelial cell line, HEp-2 (ATCC CCL23), was cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS; Invitrogen) at 37 °C in an atmosphere containing 5% CO2 and 95% air.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Bacterial strains and plasmids used in this study

Manipulation of DNA-- Chromosomal DNA from GAS was purified with a Puregene DNA isolation kit (Gentra Systems, Minneapolis, MI), and transformation of GAS by electroporation was performed as described previously (26). Plasmid DNA preparation, transformation of E. coli, and PCR were done as described previously (27). DNA sequencing was done using a BigDye terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA) and an ABI PRISM 310 DNA sequencer (Applied Biosystems).

Genome Sequence Analysis-- The complete genome sequence of GAS strain SSI-1 (M3, isolated from a patient with TSLS in Japan) was obtained from the genome data base at Osaka University (genome.gen-info.osaka-u.ac.jp/bacteria/spyo/). Potential ORFs were initially identified using GeneWorks version 2.4 (IntelliGenetics, Campbell, CA), and ORF data were analyzed by PSI- and PHI-BLAST (www.ncbi.nlm.nih.gov/BLAST/), whereas the prediction of signal sequence was performed using the WWW Signal Scan Service (bimas.dcrt.nih.gov/molbio/signal/) as described previously (28).

N-terminal Amino Acid Sequencing-- The protein was separated by SDS-7.5% PAGE and transferred to a PVDF membrane (Millipore, Bedford, MA). The membrane was stained with 0.1% Coomassie Brilliant Blue R-250 and then destained with 40% methanol. After washing with distilled water, N-terminal amino acid sequencing was performed by Edman degradation using an ABI protein sequencer model 491HT (Applied Biosystems).

Preparation of Recombinant FbaB and Anti-FbaB Serum-- An FbaB expression vector was constructed as follows, and primers used in this study are listed in Table II. The fbaB gene was amplified from chromosomal DNA of GAS strain SSI-1, and the PCR fragment was cloned into pQE30 vector (Qiagen, GmbH, Hilden, Germany). A recombinant FbaB (rFbaB) protein corresponding to amino acid positions 33-734 of FbaB (DDBJ/GenBankTM/EBI Data Bank accession number AB084272) was made, which was eliminated from the N-terminal signal peptide and C-terminal cell-anchoring region. rFbaB was purified using a QIAexpress protein purification system (Qiagen) according to the manufacturer's instructions. Rabbit polyclonal anti-FbaB serum was prepared as described previously (12) and was collected and stored at -80 °C until use. Western blotting was performed using 8 M urea extracts of GAS as described previously (29).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Primers used in this study

Integration Mutagenesis Using a Targeting Plasmid-- The PCR product of an internal portion of fbaB was ligated into pSF151 vector (30). Primers for mutagenesis are listed in Table II. The resultant plasmid pYT1185 was transformed into strain SSI-1 and enhanced green fluorescent protein (EGFP)-expressing strain SSI-1G by electroporation, and the inactivated mutant strains were selected on kanamycin-containing agar plates. The EGFP expression GAS strain was constructed as described previously (31).

Ligand Blotting-- Ligand blotting of Fn was performed as described previously (13). Briefly, human Fn (Invitrogen) was biotinylated using an ECL protein biotinylation module (Amersham Biosciences), and the concentration was adjusted to 10 µg/ml. rFbaB and 8 M urea extracts of GAS strains were electrophoresed in a 7.5 or 10% SDS-PAGE gel and transferred to PVDF membranes. The membranes were blocked overnight with 10% membrane blocking agent (Amersham Biosciences) at 4 °C and then incubated with biotinylated Fn for 1 h and horseradish peroxidase-labeled streptavidin at room temperature for 1 h. Bands were detected using ECL Western blotting detection reagents (Amersham Biosciences) and visualized by autoradiography with an x-ray film (Fuji photo film, Kanagawa, Japan) at room temperature for 5 s.

Enzyme-linked Immunosorbent Assay (ELISA)-- For measuring the binding ability of FbaB, ELISA was performed as described previously (32, 33). Fn at 1 or 10 µg/ml was coated onto 96-well flat-bottom microtiter plates (Nalge-Nunc, Naperville, IL) and left overnight at 4 °C. For blocking, 5% BSA was applied at 37 °C for 3 h. rFbaB was added and bound at 37 °C for 1 h. GAS was washed with phosphate-buffered saline (PBS) 5 times and added into wells for binding. After washing the plate with PBS containing 0.05% Tween 20, rabbit anti-FbaB or anti-M3 serum was added and incubated at 37 °C for 1 h. The plate was incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG (Cell Signaling, Beverly, MA) at 37 °C for 1 h and reacted with 0.1% p-nitrophenyl phosphate disodium salt solution (Wako, Osaka, Japan) for 15 min. Color development was measured at 405 nm using an ELISA plate reader (model Titertek MK11; Flow Laboratories, McLean, VA). All results are presented as the means of triplicate determinations, and each assay was repeated at least 3 times. Statistical analysis was performed by a nonparametric Mann-Whitney U test.

Bacterial Cell Adhesion and Invasion Assays-- Adhesion to and invasion of cells were quantified by standard procedures as described previously (12, 34). HEp-2 cells were cultured in a 24-well plate at a density of 1 × 105 cells per well and infected with 1 × 107 CFU bacteria per well (multiplicity of infection, 1:100) for 3 h. To determine bacterial adhesion, cells were washed 3 times with DMEM and lysed with 1 ml of sterile distilled water. Serial dilutions of the lysate were plated on THY agar plates to determine the number of viable GAS. For bacterial invasion, cells were washed 3 times and incubated for 1 h with DMEM containing gentamicin (100 µg/ml) and penicillin (100 units/ml). Cells were washed, lysed, and plated to count those invaded by GAS. Data are expressed as the means of the percentage of GAS recovered per well from 6 independent determinations ± S.E. The assays were repeated 3 times, and representative data are shown. Statistical analysis was performed by a nonparametric Mann-Whitney U test. All conclusions were based on p < 0.005 as significant.

Immunofluorescence Analysis-- HEp-2 cells were cultured on 8-well chamber slides (Nalge-Nunc). After infection with GAS (multiplicity of infection, 1:100), the wells were fixed with 4% paraformaldehyde and blocked with 10% FBS containing 50 µg/ml human IgG (Calbiochem). Immunofluorescence staining was performed as described previously (31). Adhered GAS was detected using the rabbit anti-M3 polyclonal antibody and Alexa Fluor 594-conjugated goat anti-rabbit IgG (Molecular Probes, Eugene, OR). Stained GAS was analyzed using a confocal laser scanning microscope (model LSM 510, Carl Zeiss, Oberkochem, Germany).

Virulence in Mice-- CD-1 outbred mice (7 weeks old, female, 20 g in weight, 10 mice per group) were purchased from Charles River Laboratories, Japan. GAS strains were grown at 37 °C to A600 values of 0.4 and washed twice with sterile PBS. They were then resuspended in sterile PBS, and concentrations were adjusted to ~4 × 107 CFU/ml. Each mouse was anesthetized with pentobarbital and injected with 0.1 ml of GAS (equivalent to 4 × 106 CFU) intraperitoneally. The mortality of infected mice was monitored every 24 h for 7 days. Statistical analysis was performed by a chi 2 test. All conclusions were based on p < 0.05 as significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Screening for Fn-binding Protein in Serotype M3 Strains-- Surface proteins were extracted with 8 M urea from M3 GAS isolates from patients with TSLS or pharyngitis (29). Twenty seven strains of M3 were initially screened for expression of Fn-binding proteins by ligand blotting. On the basis of the reactions to biotinylated Fn by autoradiography, several isolates from TSLS patients were found to express Fn-binding protein (Fig. 1C). Approximately 80- and 88-kDa proteins were found to bind Fn at a binding capability much stronger than M3 protein, which is also an Fn-binding protein (35). However, the recovery of the 80- and 88-kDa proteins was much less than M protein at 55 kDa (Fig. 1, A and B).


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 1.   Western blot analysis of 8 M urea extracts from M3 strains isolated from TSLS patients. A, Coomassie Brilliant Blue staining. B, Western blotting using rabbit anti-M3 serum. C, ligand blotting with biotinylated human Fn.

Analysis of the Genomic Region of Neighboring the fbaB Gene-- The complete genome sequencing of serotype M3 GAS strain SSI-1 from a TSLS patient was performed and annotated (DDBJ/GenBankTM/EBI Data Bank accession number BA000034). When we searched for ORFs with a calculated molecular mass of ~88 kDa and harboring an LPXTG motif from all putative ORFs, we obtained one ORF. Because it possessed putative signal sequence in the N-terminal region and cell-anchoring LPATGE sequence and Fn-binding repeat motif (www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?uid= pfam02986&version=v1.54) in the C terminus, we presumed the ORF was an Fn-binding protein and designated it FbaB. Furthermore, the deduced sequence of FbaB had identical amino acid residues in the N terminus to the N-terminal amino acid sequence of the 88-kDa band of Fn-binding protein. Fig. 2 shows the regions of the fbaB gene that were analyzed by a BLAST search. The fbaB gene was located downstream of a global negative regulator gene, nra (4), and a putative regulator gene that has been annotated as the msmR gene (36). Furthermore, there were no phage or phage-like elements in this region. The fbaB gene had a streptococcal consensus Shine-Dalgarno sequence (GGAGAG), -10 (TAGGCT), and -35 (TTGTCC) sequences (1, 11, 37) preceding the start codon ATG. The ORF consisted of 2,202 nucleotides and encoded a protein of 733 amino acid residues with a deduced molecular mass of 81 kDa, and the mature protein was calculated to be 79 kDa.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   The location and homology of the fbaB gene. A, the region neighboring the fbaB gene of GAS strain SSI-1 (M3, isolated from a patient with TSLS) and a schematic diagram of the functional domains of FbaB. The number of residues in each protein is indicated in parentheses. B, multiple sequence alignment of FbaB with homologous proteins identified by a Blast search. Comparisons of deduced amino acid sequences are shown as a percentage of the identity values between each ORF. The DDBJ/GenBankTM/EBI Data Bank accession numbers for the sequences are as follows: FbaB, AB084272; protein F2, U31980; Cpa, U49397; protein F1, L10919.

Comparisons with the deduced amino acid sequence of other GAS proteins are shown in Fig. 2B. Similarities between FbaB and another Fn-binding protein, F2, of GAS (8) were confined to the C-terminal portions, which included the Fn-binding repeats. The homology between the region from amino acids 434 to 733 of FbaB and from 741 to 1039 residues of protein F2 was 97%. FbaB also showed a 49% homology to Cpa (collagen-binding protein of GAS; see Ref. 4) in the N-terminal region. Protein F1 (1) was found to have two sections that exhibited a high similarity to FbaB.

Inactivation of the fbaB Gene and Characterization of an FbaB-deficient Mutant-- To inactivate the fbaB gene, we first constructed pYT1185 carrying the fbaB and aphA3 genes (Fig. 3A). The plasmid pYT1185 was transformed into strain SSI-1 by electroporation and integrated into the chromosomal DNA of SSI-1 by a single crossover recombination. Integration and inactivation of fbaB were demonstrated by PCR with the fbaB gene-specific forward primer and the aphA3-specific reverse primer (data not shown). A generated mutant strain, TR-47, was subjected to Western blot analysis using anti-FbaB serum, resulting that FbaB protein was not expressed on the bacterial cell surface (Fig. 3B). We observed that the inactivation of fbaB resulted in disappearance of both 80- and 88-kDa proteins. The 80-kDa Fn-binding protein was considered to be a degradation product of the 88-kDa Fn-binding protein. These results demonstrated that the fbaB gene encodes a novel Fn-binding protein, FbaB. In order to investigate the ability of FbaB with live bacteria, we examined the difference between wild type strain SSI-1 and FbaB-deficient mutant TR-47 by ELISA using Fn-coated plates. Increasing densities of organisms were incubated on the Fn-coated microtiter plates. The binding activities were quantified using rabbit anti-M3 polyclonal antibody and alkaline phosphatase-conjugated goat anti-rabbit IgG (Fig. 3, C and D). Both strains bound to immobilized Fn in a cell density-dependent manner, although the affinity of the FbaB- mutant, TR-47, was lower than that of wild type strain SSI-1. These results clearly show that FbaB functions as an Fn-binding protein on the surface of GAS and suggest that the remaining Fn-binding ability of TR-47 may be ascribed to M3 protein (35).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Functional analysis of an FbaB-deficient mutant. A, targeted mutagenesis of the fbaB gene in GAS strain SSI-1 (M3, isolated from a TSLS patient). pYT1185 was found to possess an internal fragment of the fbaB gene and the aphA3 gene (kanamycin-resistant). By using electroporation, the FbaB-deficient mutant strain TR-47 was obtained by a single crossover recombination. B, Western blot analysis with anti-FbaB and Fn binding of 8 M urea extracts of GAS strains. Lane a, Coomassie Brilliant Blue staining. Lane b, Western blotting using anti-FbaB. Lane c, binding to biotinylated human Fn (10 µg/ml). C and D, binding of GAS strains to immobilized Fn (C, 1 µg/ml; D, 10 µg/ml). Fn-coated microtiter plates were incubated with various densities of GAS strains. Bound GAS organisms were detected using the anti-M3 antibody. Binding activity is presented as A405 values. These experiments were performed in triplicate, and data represent the mean of triplicate samples from one representative experiment. S.E. results are represented by vertical lines. *, p < 0.05.

Distribution of the fbaB Gene and Fibronectin Binding to FbaB Protein from Various GAS Strains-- The distribution of the fbaB gene was examined by PCR, and the expression of FbaB protein was investigated by Western blotting with anti-FbaB serum and ligand blotting with biotinylated Fn (Table III). The fbaB gene was found exclusively on the chromosomes of the M3 and M18 strains of GAS. In contrast, anti-FbaB serum and biotinylated Fn reacted with the cell surface extracts of GAS isolated from TSLS patients but not from pharyngitis patients.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Distribution of the fbaB gene and FbaB protein among various M serotype strains of group A streptococci

rFbaB was separated by SDS-PAGE and transferred to a PVDF membrane, followed by incubation with biotinylated Fn. It was demonstrated that immobilized rFbaB bound strongly to soluble Fn (Fig. 4A). To analyze the binding activity of soluble rFbaB, various concentrations of rFbaB were added to Fn-coated microtiter plates, and bound rFbaB was quantified using rabbit anti-FbaB serum and alkaline phosphatase-conjugated goat anti-rabbit IgG antibody. The results showed that soluble rFbaB bound to immobilized Fn in a dose-dependent manner (Fig. 4B). BSA (Sigma) served as a negative control and did not bind to Fn.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Fn binding activity of recombinant FbaB. A, binding of Fn to rFbaB. Lane a, Coomassie Brilliant Blue staining. Lane b, binding to biotinylated human Fn (10 µg/ml). B, analysis of Fn binding activity by ELISA. Fn-coated microtiter plates (1 µg/ml) were blocked with BSA and bound with various concentrations of rFbaB for 1 h at 37 °C. Fn binding of rFbaB was detected with anti-FbaB serum. Three experiments were performed in triplicate, and data represent the mean of triplicate wells from one representative experiment. S.E. were represented by vertical lines.

Localization of FbaB from GAS-- It was important to determine whether FbaB is surface-associated or localized intracellularly. Immunofluorescent microscopy using anti-FbaB and secondary Alexa Fluor 594-conjugated antibodies revealed the polar distribution of FbaB on the bacterial cell surface (Fig. 5, red image). The EGFP-expressed strain SSI-1G was observed as a green image. Based on these results and those from ELISA with live GAS (Fig. 3, C and D), along with the presence of the LPXTG motif in the C terminus, we concluded that FbaB was localized on the surface of GAS, and we hypothesized that FbaB functions as an adhesin or an invasin.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Polar localization of FbaB. A, distribution of FbaB on GAS surface by immunofluorescence analysis. Panel a, FbaB was visualized using rabbit anti-FbaB serum and Alexa Fluor 594-conjugated goat anti-rabbit IgG (red image). Panel b, EGFP expression of GAS strain SSI-1G can be observed as the green image. Panel c, merge image. B, panel a, with rabbit preimmune serum and Alexa Fluor 594-conjugated goat anti-rabbit IgG. Panel b, EGFP expression of GAS strain SSI-1G. Panel c, merge image. Bars indicate 1 µm.

Role of FbaB in Bacterial Invasion and Mouse Lethality-- To investigate the role of FbaB, adhesion and invasion efficiencies of strain SSI-1 and its mutant TR-47 were compared. Adhesion to and invasion of the HEp-2 cells by these strains were measured, respectively. Adhesion to and invasion of FbaB-deficient mutant, TR-47, were reduced ~6-fold as compared with those of SSI-1, respectively (p < 0.005; Fig. 6).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Adhesion to and invasion of HEp-2 cells by GAS strains SSI-1 (wild type) and TR-47 (FbaB-). GAS strains were suspended in DMEM containing 10% FBS and added to HEp-2 cells (multiplicity of infection, 100:1; 100 bacteria per HEp-2 cells) as described under "Experimental Procedures." A, the percentage of adhesion was calculated as (CFU of adhesion and invasion/CFU of inoculum) × 100. B, the percentage of invasion was calculated as (CFU of invasion/CFU of inoculum) × 100. Three experiments were performed, and the data represent the mean from six wells from one representative experiment. S.E. results are represented by vertical lines. *, p < 0.005.

The contribution of FbaB in adhesion to and invasion of epithelial cells was further studied (Fig. 7). Invasion of HEp-2 cells was assessed using EGFP expression in strain SSI-1G (EGFP+, FbaB+) and its isogenic mutant TR-47G (EGFP+, FbaB-). The adhesion of GAS to the surface of HEp-2 cells was visualized by staining with anti-M3 and Alexa Fluor 594-conjugated secondary antibodies (red image). The adhesion and invasion abilities of TR-47G were clearly abrogated when compared with wild type strain SSI-1G. The above results indicate that FbaB serves as adhesin and an invasin with epithelial cells.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 7.   In vitro entry of GAS into HEp-2 cells as seen by immunofluorescent microscopy. Organisms were visualized by immunofluorescence staining as described under "Experimental Procedures." The infected GAS strains are as follows. A, SSI-1G (EGFP expression GAS strain; EGFP+, FbaB+); B, TR-47G (isogenic mutant of strain SSI-1G; EGFP+, FbaB-). After infection, the adhered GAS organisms were stained with rabbit anti-M3 antibody and visualized with Alexa Fluor 594-conjugated anti-rabbit IgG (seen as red images). The invaded GAS organisms can be observed as green images by the expression of EGFP. Bars indicate 10 µm. Enlargements (panels a and b) correspond to area enclosed by squares in A and B, respectively. Bars indicate 1 µm.

Lack of FbaB results in the reduction of mouse mortality after challenge with GAS. The wild type strain SSI-1 yielded 80% mortality on day 2 and 90% mortality on day 4, whereas that of its isogenic mutant strain TR-47 was only 40% on day 2 (Fig. 8). These results strongly suggest that FbaB contributed to the virulence of the GAS strain that resulted in mouse mortality.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   Survival plots of GAS-infected mice. Approximately 4 × 106 CFU of GAS was injected intraperitoneally into mice (n = 10). The number of surviving mice was monitored daily. *, p < 0.05 (chi 2 test).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial adhesion to host epithelial cells through extracellular matrix proteins is considered to promote both colonization and infection. Various bacterial pathogens possess Fn-binding proteins including Staphylococcus aureus (38), Listeria monocytogenes (39), and Salmonella enterica (40). A number of anchored proteins on the surface of GAS have shown binding ability of Fn. Furthermore, a correlation exists between the distribution of a particular Fn-binding protein and specific M serotypes, and a population of the M3 and M18 strains is known to be highly virulent (14-17, 41). In the present study, we elucidated a novel Fn-binding protein selectively isolated from M3 and M18 strains, which we termed FbaB.

Jaffe et al. (8) reported that a highly homologous repeat domain in protein F2 is the main Fn-binding region when compared with that of protein F1. The present results showed that the putative Fn-binding domain of FbaB was highly conserved at the C-terminal region (Fig. 2), and the domain contains three Fn-binding repeats consisting of 36-, 37-, and 38-amino acid residues. McGavin et al. (42) suggested that a contiguous sequence of 8 amino acids is essential for Fn binding activity in FnBB of Streptococcus dysgalactiae. We observed the conserved sequence, HFDNXXP, at amino acids 671-684 in FbaB protein. Furthermore, the fbaB gene was shown to possess a potential ribosome-binding site and promoter-like sequences (-10 and -35) upstream of the start codon and a putative signal sequence in the N terminus and a cell-anchoring LPXTG motif in the C terminus. Thus, it is reasonable to conclude that FbaB is expressed on the surface and has Fn binding ability.

To examine whether FbaB works as an adhesin and an invasin to host cells, it was important to determine the localization of the protein. The 8 M urea extracts of several M3 GAS strains strongly reacted with biotinylated Fn by ligand blotting (Fig. 1). Furthermore, the results of immunofluorescence analysis (Fig. 5) and ELISA with Fn-coated microtiter plates and live organisms (Fig. 3, C and D) clearly indicated that FbaB was a surface-associated protein. When a correlation between the presence of the fbaB gene and specific M serotypes was observed by PCR, the fbaB gene was found solely in M3 and M18 (Table I). We also found that 61.5% of the M3 strains isolated from TSLS patients expressed FbaB protein, whereas none of those from pharyngitis patients did (Table I). These results suggest that the expression of FbaB is highly associated with M3 organisms from TSLS. Moreover, streptococcal Fn-binding proteins are important virulence factors that play an essential role in adherence and invasion of host cells (43). We found that FbaB interacted with human epithelial cells, whereas inactivation of the fbaB gene inhibited the FbaB- mutant from adhesion to and invasion of HEp-2 cells (Figs. 6 and 7). Therefore, we hypothesized that the development of severe invasive diseases and TSLS could be ascribed to the actual expression of fbaB. However, to confirm this relationship, we will perform further tests using a number of isolates from many countries.

The fbaB gene was found located downstream of a global regulatory gene, nra (Fig. 2). Podbielski et al. (4) reported that Nra negatively regulates Cpa and protein F2 transcription as well as its own transcription and that the nra gene is primarily transcribed. Based on their relative locations and a preliminary study (data not shown), we speculated that the fbaB gene is normally controlled under the negative regulator Nra. Podbielski et al. (4) also predicted that the negative regulatory activity of Nra could be attributed to the essential sequence that would function as an Nra-binding box. Several regulatory proteins in transcription utilize DNA binding activity for the regulator-binding box, which exists in the upstream region of the structural gene (44). For example, the Mga-binding box and RofA-binding box from GAS have been reported by McIver et al. (45) and Fogg and Caparon (46), respectively. However, in the present study we could not find the putative Nra-binding box (GCTTCTAAACTT) or similar sequences in the region upstream of the fbaB gene of M3 strain SSI-1.

Fn is a large and multifunctional molecule found in serum and basement membranes, and it is known to bind to a wide variety of proteins and host cells by a surface integrin (47). Various pathogenic bacteria bind to Fn and use it for mediation by forming a bridge across the host cells and then facilitating the escape from human immune systems by pretending to be autogenous components. Several reports (34, 48) have shown that adherence to and invasion of epithelial cells require both soluble Fn and integrin expression on the cell surface, which may be explained by the possibility that the Fn-binding protein cannot bind to integrins directly. Stockbauer et al. (49) identified three major SpeBs, a cysteine protease of GAS variants, and showed that one of these variants, SpeB2, contains an RGD motif that was found to be a minimum integrin-binding sequence (50). Furthermore, they demonstrated that only SpeB2, which is usually produced by highly virulent M serotype strains, binds to integrins. Because FbaB contained an RGD motif at amino acid positions 135-137 (Fig. 2), we speculated that it might be an integrin-recognizing ligand with the ability to bind to an integrin. Taken together, these results demonstrate that FbaB may promote bacterial adhesion to host cell surfaces and also contribute to the colonization and invasion of organisms.

We also showed that FbaB indicated two molecular sizes by Western blot and ligand blot analyses (Figs. 1 and 3B). A band of 80-kDa FbaB from 8 M urea extract reacted with Fn stronger than an 88-kDa protein, which was similar to the pattern shown between M1 protein and immunoglobulins by Raeder et al. (20). Their report demonstrated that SpeB, a cysteine protease, cleaved M1 protein to generate a protein with a higher level of immunoglobulin binding activity. To test the hypothesis that FbaB is also modified by SpeB protein, we incubated rFbaB with various concentrations of recombinant SpeB, which revealed two major bands (molecular mass of 80 and 88 kDa, data not shown). These results suggest that the proteolytic reaction by SpeB affects not only host cells but also the surface proteins of GAS to increase their virulence activities. This modification may be associated with the invasive capability of GAS and a key factor for analyzing the change to invasive strains. Furthermore, the cleavage of FbaB by SpeB in the N terminus may contribute to its escape from the host immune system by raising a distinct antigenicity. Although it is unclear how bacterial adhesion to and invasion of host cells affect streptococcal diseases in humans, findings from many studies have shown that intracellular invasion is associated with an important role of streptococcal virulence. Further study of FbaB may elucidate the mechanisms involved with invasive streptococcal infections, including bacterial colonization and the spread into deeper organs.

    ACKNOWLEDGEMENTS

We thank T. Murai, H. Watanabe, C. Katsukawa, and E. Hanski for providing the streptococcal strains. We also thank to Mikiyo Yamaguchi and Masaya Yamaguchi for help with this work.

    FOOTNOTES

* This work was supported by grants from Japan Science and Technology Corp., the Japan Society for Promotion of Science, the Ministry of Health, Labour and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession number(s) AB084272.

To whom correspondence should be addressed: Dept. of Oral and Molecular Microbiology, Osaka University Graduate School of Dentistry, 1-8, Yamadaoka, Suita-Osaka 565-0871, Japan. Tel.: 81-6-6879-2898; Fax: 81-6-6878-4755; E-mail: kawabata@dent.osaka-u.ac.jp.

Published, JBC Papers in Press, September 30, 2002, DOI 10.1074/jbc.M209133200

2 I. Nakagawa, K. Kurokawa, M. Nakata, A. Yamashita, Y. Tomiyasu, N. Okahashi, S. Kawabata, K. Yamasaki, T. Shiba, T. Yasunaga, M. Hattori, H. Hayashi, and S. Hamada, S., submitted for publication.

    ABBREVIATIONS

The abbreviations used are: GAS, group A streptococcus; TSLS, toxic shock-like syndrome; Fn, fibronectin; FbaB, fibronectin-binding protein of group A streptococci type B; EGFP, enhanced green fluorescent protein; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; FBS, fetal bovine serum; BSA, bovine serum albumin; DMEM, Dulbecco's modified Eagle's medium; PVDF, polyvinylidene difluoride; CFU, colony-forming units; ORF, open reading frame.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sela, S., Aviv, A., Tovi, A., Burstein, I., Caparon, M. G., and Hanski, E. (1993) Mol. Microbiol. 10, 1049-1055[Medline] [Order article via Infotrieve]
2. Terao, Y., Kawabata, S., Kunitomo, E., Nakagawa, I., and Hamada, S. (2002) Infect. Immun. 70, 993-997[Abstract/Free Full Text]
3. Eichenbaum, A., Green, B. D., and Scott, J. R. (1996) Infect. Immun. 64, 1956-1960[Abstract]
4. Podbielski, A., Woischnik, M., Leonard, B. A., and Schmidt, K. H. (1999) Mol. Microbiol. 31, 1051-1064[CrossRef][Medline] [Order article via Infotrieve]
5. Frithz, E., Heden, L. O., and Lindahl, G. (1989) Mol. Microbiol. 3, 1111-1119[Medline] [Order article via Infotrieve]
6. Thern, A., Stenberg, L., Dahlbäck, B., and Lindhal, G. (1995) J. Immunol. 154, 375-386[Abstract]
7. Talay, S. R., Valentin-Weigand, P., Timmis, K. N., and Chhatwal, G. S. (1994) Mol. Microbiol. 13, 531-539[Medline] [Order article via Infotrieve]
8. Jaffe, J., Natanson-Yaron, S., Caparon, M. G., and Hanski, E. (1996) Mol. Microbiol. 21, 373-384[CrossRef][Medline] [Order article via Infotrieve]
9. Kreikemeyer, B., Talay, S. R., and Chhatwal, G. S. (1995) Mol. Microbiol. 17, 137-145[Medline] [Order article via Infotrieve]
10. Courtney, H. S., Hasty, D. L., Li, Y., Chiang, H. C., Thacker, J. L., and Dale, J. B. (1999) Mol. Microbiol. 32, 89-98[CrossRef][Medline] [Order article via Infotrieve]
11. Rocha, C. L., and Fischetti, V. A. (1999) Infect. Immun. 67, 2720-2728[Abstract/Free Full Text]
12. Terao, Y., Kawabata, S., Kunitomo, E., Murakami, J., Nakagawa, I., and Hamada, S. (2001) Mol. Microbiol. 42, 75-86[CrossRef][Medline] [Order article via Infotrieve]
13. Natanson, S., Sela, S., Moses, A. E., Musser, J. M., Caparon, M. G., and Hanski, E. (1995) J. Infect. Dis. 171, 871-878[Medline] [Order article via Infotrieve]
14. Stevens, D. L., Tanner, M. H., Winshop, J., Swarts, R., Ries, K. M., Schlievert, P. M., and Kaplan, E. (1989) N. Engl. J. Med. 321, 1-7[Abstract]
15. Hauser, A. R., Stevens, D. L., Kaplan, E. D., and Schlievert, P. M. (1991) J. Clin. Microbiol. 29, 1562-1567[Abstract/Free Full Text]
16. Inagaki, Y., Myouga, F., Kawabata, H., Yamai, S., and Watanabe, H. (2000) J. Infect. Dis. 181, 975-983[CrossRef][Medline] [Order article via Infotrieve]
17. Smoot, J. C., Barbian, K. D., Van Gompel, J. J., Smoot, L. M., Chaussee, M. S., Sylva, G. L., Sturdevant, D. E., Ricklefs, S. M., Porcella, S. F., Parkins, L. D., Beres, S. B., Campbell, D. S., Smith, T. M., Ahang, Q., Kapur, V., Daly, J. A., George Veasy, L., and Musser, J. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4668-4673[Abstract/Free Full Text]
18. Ferretti, J. J., McShan, W. M., Ajdic, D., Savic, D. J., Savic, G., Lyon, K., Primeaux, C., Sezate, S., Suvorov, A. N., Kenton, S., Lai, H. S., Lin, S. P., Qian, Y., Jia, H. G., Najar, F. Z., Ren, Q., Zhu, H., Song, L., White, J., Yuan, X., Clifton, S. W., Roe, B. A., and McLaughlin, R. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4658-4663[Abstract/Free Full Text]
19. Beres, S. B., Sylva, G. L., Barbian, K. D., Lei, B., Hoff, J. S., Mammarella, N. D., Liu, M. Y., Smoot, J. C., Porcella, S. F., Parkins, L. D., Campbell, D. S., Smith, T. M., McCormick, J. K., Leung, D. Y. M., Schlievert, P. M., and Musser, J. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10078-10083[Abstract/Free Full Text]
20. Raeder, R., Woischnik, M., Podbielski, A., and Boyle, M. D. (1998) Res. Microbiol. 149, 539-548[Medline] [Order article via Infotrieve]
21. Fischetti, V. A., Pancholi, V., and Schneewind, O. (1990) Mol. Microbiol. 4, 1603-1605[Medline] [Order article via Infotrieve]
22. Rasmussen, M., Müller, H., and Björck, L. (1999) J. Biol. Chem. 274, 15336-15344[Abstract/Free Full Text]
23. Rasmussen, M., Edén, A., and Björck, L. (2000) Infect. Immun. 68, 6370-6377[Abstract/Free Full Text]
24. Whatmore, A. M. (2001) Microbiology 147, 419-429[Abstract/Free Full Text]
25. Murakami, J., Kawabata, S., Terao, Y., Kikuchi, K., Totsuka, K., Tamaru, A., Katsukawa, C., Moriya, K., Nakagawa, I., Morisaki, I., and Hamada, S. (2002) Epidemiol. Infect. 128, 397-404[CrossRef][Medline] [Order article via Infotrieve]
26. Caparon, M. G., and Scott, J. R. (1991) Methods Enzymol. 204, 556-586[Medline] [Order article via Infotrieve]
27. Sambrook, J., and Russell, D. W. (2001) Molecular Cloning: A Laboratory Manual , 3rd Ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
28. von Heijne, G. (1986) Nucleic Acids Res. 14, 4683-4690[Abstract/Free Full Text]
29. Hamada, S., Horikoshi, T., Minami, T., Kawabata, S., Hiraoka, J., Fujiwara, T., and Ooshima, T. (1991) Infect. Immun. 59, 4161-4167[Abstract/Free Full Text]
30. Tao, L., LeBlanc, D. J., and Ferretti, J. (1992) Gene (Amst.) 120, 105-110[CrossRef][Medline] [Order article via Infotrieve]
31. Nakagawa, I., Nakata, M., Kawabata, S., and Hamada, S. (2001) Cell. Microbiol. 3, 395-405[CrossRef][Medline] [Order article via Infotrieve]
32. Massey, R. C., Kantzanou, M, N., Fowler, T., Day, N. P. J., Schofield, K., Wann, E. R., Berendt, A. R., Höök, M., and Peacock, S. J. (2001) Cell. Microbiol. 3, 839-851[CrossRef][Medline] [Order article via Infotrieve]
33. Beckmann, C., Waggoner, J. D., Harris, T. O., Tamura, G. S., and Rubens, C. E. (2002) Infect. Immun. 70, 2869-2876[Abstract/Free Full Text]
34. Ozeri, V., Rosenshine, I., Mosher, D. F., Fässler, R., and Hanski, E. (1998) Mol. Microbiol. 30, 625-637[CrossRef][Medline] [Order article via Infotrieve]
35. Schmidt, K., Mann, K., Cooney, J., and Köhler, W. (1993) FEMS Immunol. Med. Microbiol. 7, 135-144[CrossRef][Medline] [Order article via Infotrieve]
36. Russell, R. R., Aduse-Opoku, J., Sutcliffe, I. C., Tao, L., and Ferretti, J. J. (1992) J. Biol. Chem. 267, 4631-4637[Abstract/Free Full Text]
37. Huang, T. T., Malke, H., and Ferretti, J. J. (1989) Mol. Microbiol. 3, 197-205[CrossRef][Medline] [Order article via Infotrieve]
38. Signäs, C., Raucci, G., Jönsson, K., Lindgren, P., Anantharamaiah, G. M., Höök, M., and Lindberg, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 699-703[Abstract/Free Full Text]
39. Gilot, P., Andre, P., and Content, J. (1999) Infect. Immun. 67, 6698-6701[Abstract/Free Full Text]
40. Kingsley, R. A., Santos, R. L., Keestra, A. M., Adams, L. G., and Baumler, A. J. (2002) Mol. Microbiol. 43, 895-905[CrossRef][Medline] [Order article via Infotrieve]
41. Talkington, D. F., Schwartz, B., Black, C. M., Todd, J. K., Elliott, J., Breiman, R. F., and Facklam, R. R. (1993) Infect. Immun. 61, 3369-3374[Abstract/Free Full Text]
42. McGavin, M. J., Gurusiddappa, S., Lindgren, P. E., Lindberg, M., Raucci, G., and Höök, M. (1993) J. Biol. Chem. 268, 23946-23953[Abstract/Free Full Text]
43. Canningham, M. W. (2000) Clin. Microbiol. Rev. 13, 470-511[Abstract/Free Full Text]
44. McIver, K. S., and Myles, R. L. (2002) Mol. Microbiol. 43, 1591-1601[CrossRef][Medline] [Order article via Infotrieve]
45. McIver, K. S., Heath, A. S., Green, B. D., and Scott, J. R. (1995) J. Bacteriol. 177, 6619-6624[Abstract/Free Full Text]
46. Fogg, G. C., and Caparon, M. G. (1997) J. Bacteriol. 179, 6172-6180[Abstract/Free Full Text]
47. Pytela, R., Pierschbacher, M. D., and Ruoslahti, E. (1985) Cell 40, 191-198[CrossRef][Medline] [Order article via Infotrieve]
48. Ozeri, V., Rosenshine, I., Ben-Ze'Ev, A., Bokoch, G. M., Jou, T. S., and Hanski, E. (2001) Mol. Microbiol. 41, 561-573[CrossRef][Medline] [Order article via Infotrieve]
49. Stockbauer, K. E., Magoun, L., Liu, M., Burns, E. H., Gubba, S., Renish, S., Pan, X., Bodary, S. C., Baker, E., Coburn, J., Leong, J. M., and Musser, J. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 242-247[Abstract/Free Full Text]
50. Pierschbacher, M. D., and Ruoslahti, E. (1984) Nature 309, 30-33[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Infect. Immun.Home page
M. Nakata, T. Koller, K. Moritz, D. Ribardo, L. Jonas, K. S. McIver, T. Sumitomo, Y. Terao, S. Kawabata, A. Podbielski, et al.
Mode of Expression and Functional Characterization of FCT-3 Pilus Region-Encoded Proteins in Streptococcus pyogenes Serotype M49
Infect. Immun., January 1, 2009; 77(1): 32 - 44.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Yamaguchi, Y. Terao, Y. Mori, S. Hamada, and S. Kawabata
PfbA, a Novel Plasmin- and Fibronectin-binding Protein of Streptococcus pneumoniae, Contributes to Fibronectin-dependent Adhesion and Antiphagocytosis
J. Biol. Chem., December 26, 2008; 283(52): 36272 - 36279.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Terao, Y. Mori, M. Yamaguchi, Y. Shimizu, K. Ooe, S. Hamada, and S. Kawabata
Group A Streptococcal Cysteine Protease Degrades C3 (C3b) and Contributes to Evasion of Innate Immunity
J. Biol. Chem., March 7, 2008; 283(10): 6253 - 6260.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Gillen, H. S. Courtney, K. Schulze, M. Rohde, M. R. Wilson, A. M. Timmer, C. A. Guzman, V. Nizet, G. S. Chhatwal, and M. J. Walker
Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete
J. Biol. Chem., March 7, 2008; 283(10): 6359 - 6366.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
L. Baldassarri, R. Creti, M. Imperi, S. Recchia, M. Pataracchia, and G. Orefici
Detection of Genes Encoding Internalization-Associated Proteins in Streptococcus pyogenes Isolates from Patients with Invasive Diseases and Asymptomatic Carriers
J. Clin. Microbiol., April 1, 2007; 45(4): 1284 - 1287.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
S. Lizano, F. Luo, and D. E. Bessen
Role of Streptococcal T Antigens in Superficial Skin Infection
J. Bacteriol., February 15, 2007; 189(4): 1426 - 1434.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
Z. Kratovac, A. Manoharan, F. Luo, S. Lizano, and D. E. Bessen
Population Genetics and Linkage Analysis of Loci within the FCT Region of Streptococcus pyogenes
J. Bacteriol., February 15, 2007; 189(4): 1299 - 1310.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
A. Podbielski
Flexible Architecture of the Streptococcus pyogenes FCT Genome Region: Finally the Clue for Understanding Purulent Skin Diseases and Long-Term Persistence?{triangledown}
J. Bacteriol., February 15, 2007; 189(4): 1181 - 1184.
[Full Text] [PDF]


Home page
JDRHome page
A. Amano
The Oral Microbiology Research of Shigeyuki Hamada in the Pre-genomic Era
Journal of Dental Research, June 1, 2006; 85(6): 501 - 504.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Terao, M. Yamaguchi, S. Hamada, and S. Kawabata
Multifunctional Glyceraldehyde-3-phosphate Dehydrogenase of Streptococcus pyogenes Is Essential for Evasion from Neutrophils
J. Biol. Chem., May 19, 2006; 281(20): 14215 - 14223.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
C. Lembke, A. Podbielski, C. Hidalgo-Grass, L. Jonas, E. Hanski, and B. Kreikemeyer
Characterization of Biofilm Formation by Clinically Relevant Serotypes of Group A Streptococci
Appl. Envir. Microbiol., April 1, 2006; 72(4): 2864 - 2875.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. McArthur, E. Medina, A. Mueller, J. Chin, B. J. Currie, K. S. Sriprakash, S. R. Talay, G. S. Chhatwal, and M. J. Walker
Intranasal Vaccination with Streptococcal Fibronectin Binding Protein Sfb1 Fails To Prevent Growth and Dissemination of Streptococcus pyogenes in a Murine Skin Infection Model
Infect. Immun., December 1, 2004; 72(12): 7342 - 7345.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
V. Ramachandran, J. D. McArthur, C. E. Behm, C. Gutzeit, M. Dowton, P. K. Fagan, R. Towers, B. Currie, K. S. Sriprakash, and M. J. Walker
Two Distinct Genotypes of prtF2, Encoding a Fibronectin Binding Protein, and Evolution of the Gene Family in Streptococcus pyogenes
J. Bacteriol., November 15, 2004; 186(22): 7601 - 7609.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Okamoto, S. Kawabata, Y. Terao, H. Fujitaka, Y. Okuno, and S. Hamada
The Streptococcus pyogenes Capsule Is Required for Adhesion of Bacteria to Virus-Infected Alveolar Epithelial Cells and Lethal Bacterial-Viral Superinfection
Infect. Immun., October 1, 2004; 72(10): 6068 - 6075.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Voyich, K. R. Braughton, D. E. Sturdevant, C. Vuong, S. D. Kobayashi, S. F. Porcella, M. Otto, J. M. Musser, and F. R. DeLeo
Engagement of the Pathogen Survival Response Used by Group A Streptococcus to Avert Destruction by Innate Host Defense
J. Immunol., July 15, 2004; 173(2): 1194 - 1201.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Oehmcke, A. Podbielski, and B. Kreikemeyer
Function of the Fibronectin-Binding Serum Opacity Factor of Streptococcus pyogenes in Adherence to Epithelial Cells
Infect. Immun., July 1, 2004; 72(7): 4302 - 4308.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
P. Nyberg, M. Rasmussen, U. von Pawel-Rammingen, and L. Bjorck
SpeB modulates fibronectin-dependent internalization of Streptococcus pyogenes by efficient proteolysis of cell-wall-anchored protein F1
Microbiology, May 1, 2004; 150(5): 1559 - 1569.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Kreikemeyer, S. Oehmcke, M. Nakata, R. Hoffrogge, and A. Podbielski
Streptococcus pyogenes Fibronectin-binding Protein F2: EXPRESSION PROFILE, BINDING CHARACTERISTICS, AND IMPACT ON EUKARYOTIC CELL INTERACTIONS
J. Biol. Chem., April 16, 2004; 279(16): 15850 - 15859.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
B. J. M. Vlaminckx, E. M. Mascini, J. Schellekens, L. M. Schouls, A. Paauw, A. C. Fluit, R. Novak, J. Verhoef, and F. J. Schmitz
Site-Specific Manifestations of Invasive Group A Streptococcal Disease: Type Distribution and Corresponding Patterns of Virulence Determinants
J. Clin. Microbiol., November 1, 2003; 41(11): 4941 - 4949.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/49/47428    most recent
M209133200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terao, Y.
Right arrow Articles by Hamada, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terao, Y.
Right arrow Articles by Hamada, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement